Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05498272 · ClinicalTrials.gov registry record · Phase 2
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
A Phase 2 study of Prostate Cancer and BRCA1 Mutation, sponsored by Rana McKay, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 6
- Study locations
NCT05498272: Recruiting Phase 2 study of Prostate Cancer and BRCA1 Mutation, sponsored by Rana McKay, MD.
NCT05498272 is a Phase 2 study of Prostate Cancer and BRCA1 Mutation that is actively recruiting participants, run by Rana McKay, MD. The registered enrollment target is 32 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05498272, a Phase 2 study of Prostate Cancer and BRCA1 Mutation, is actively recruiting participants, sponsored by Rana McKay, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all patients retrospectively. Eligible patients will receive treatment with olaparib + LHRH agonist. Following 6 months of therapy, patients will undergo RP with mandatory lymph node dissection. The lymph node dissection template will be at the discretion of the treating urologist. RP specimens will undergo pathology blinded independent central review. Following RP, patients will be followed for testosterone recovery and PSA progression.
Primary Outcome
Assess pCR rate. pCR will be defined as no residual disease in the RP specimen by blinded central pathology review.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG LHRH agonist
Study Locations (6)
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- University of California San Diego - Moores Cancer Center - La Jolla
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Ohio
- University of Cincinnati - Cincinnati
Pennsylvania
- Penn Medicine Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05498272 shows while recruiting
NCT05498272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT05498272 lists 6 locations in 5 states (New York, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT05498272 about?
NCT05498272 is a clinical study titled "Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations". Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed ger...
What is the current status of trial NCT05498272?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2023-02-01. Estimated completion is 2026-12.
What conditions does trial NCT05498272 study?
This clinical trial studies the following conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, High-Risk Cancer, Prostatic Adenocarcinoma.
What interventions are being tested in trial NCT05498272?
The interventions under investigation include: Olaparib (DRUG), LHRH agonist (DRUG).
Who is sponsoring clinical trial NCT05498272?
This trial is sponsored by Rana McKay, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05498272 being conducted?
This trial has 6 study locations across California, Maryland, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05498272's enrollment target sits among peer trials
32 566th of 735 higher than 159 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI